JPMorgan upgrades Phibro Animal Health stock rating to Overweight on strong results

JPMorgan upgraded Phibro Animal Health (PAHC) to Overweight from Neutral, raising its price target to $35.00 from $25.00, citing strong operational execution and better-than-expected integration of the Zoetis MFA business acquisition, which is driving higher margins and improved EPS/EBITDA. This follows Phibro's Q3 2025 results, which significantly surpassed revenue and EPS expectations with 32% year-over-year revenue growth, and an optimistic FY2025 outlook projecting 59-66% adjusted EBITDA growth. Despite the stock's recent strong performance, JPMorgan sees further upside potential given favorable estimates and an attractive valuation of approximately 11 times FY 2026 earnings per share.

Analysis

JPMorgan's upgrade of Phibro Animal Health (PAHC) to Overweight with a price target increase to $35 from $25 is underpinned by the company's strong operational execution and the successful integration of its acquisition from Zoetis (ZTS). This strategic move is reportedly tracking ahead of schedule and generating higher-than-anticipated margins, directly enhancing EPS and EBITDA. This positive analyst action is corroborated by Phibro's impressive third-quarter 2025 financial results, which significantly surpassed expectations with a revenue of $347.8 million against a $309.5 million forecast, marking a 32% year-over-year increase. The Animal Health segment was the primary driver, with 42% growth fueled by the new acquisition. Further reinforcing this bullish outlook, the company has issued strong guidance for the full fiscal year 2025, projecting adjusted EBITDA growth between 59% and 66%. Despite the stock's substantial appreciation of nearly 70% over the past year, JPMorgan justifies its position by citing a favorable valuation of approximately 11 times fiscal year 2026 earnings per share, suggesting further upside potential.

Key Decisions for Investors

• The confluence of a significant earnings beat, robust forward guidance, and a major analyst upgrade suggests the stock's upward momentum is fundamentally justified, warranting a review of positions against the new $35 price target.
• Despite the stock trading near its 52-week high, the valuation of approximately 11 times FY 2026 EPS may present a compelling entry or accumulation point for investors seeking growth at a reasonable valuation.
• Investors should closely monitor future quarterly reports for continued execution on the ZTS MFA business integration and margin expansion, as this acquisition is the primary driver of the revised growth and profitability expectations.